Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)

European Journal of Pharmacology

Volumn 461, Issue 2-3, 2003, Pages 159-169

  Cheng, Zhong Jian ^a   Finckenberg, Piet ^a   Louhelainen, Marjut ^a   Merasto, Saara ^a   Tikkanen, Ilkka ^b   Vapaatalo, Heikki ^a   Mervaala, Eero M A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Angiotensin II; Cyclooxygenase; Heart; Kidney; Prostanoid; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LOSARTAN; MESSENGER RNA; PROSTANOID; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL INJURY; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; ENZYME INHIBITION; GENE; GENE EXPRESSION; HEART; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; INFLAMMATION; KIDNEY; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENIN 2 GENE; TRANSGENIC MOUSE;

EID: 0037436028     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01307-4     Document Type: Article

References (42)

1. Alexander R.W. Theodore Cooper memorial lecture. Hypertension and the pathogenesis of atherosclerosis, oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 25:1995;155-161.
2. Bohm M., Lee M., Kreutz R., Kim S., Schinke M., Djavidani B., Wagner J., Kaling M., Wienen W., Bader M., Ganten D. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin system gene expression and cardiovascular functions. J. Hypertens. 13:1995;891-899.
3. Breyer M.D., Harris R.C. Cyclooxygenase 2 and the kidney. Curr. Opin. Nephrol. Hypertens. 10:2001;89-98.
4. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 103:2001;904-912.
5. Buttar N.S., Wang K.K., Leontovich O., Westcott J.Y., Pacifico R.J., Anderson M.A., Krishnadath K.K., Lutzke L.S., Burgart L.J. Chemoprevention of esophageal adenocarcinoma by cyclooxygenase-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 122:2002;1101-1112.
6. Cheng H.F., Wang J.L., Zhang M.Z., Miyazaki Y., Ichikawa I., McKanna J.A., Harris R.C. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J. Clin. Invest. 103:1999;953-961.
7. Cowley A.W.J. Long-term control of arterial blood pressure. Physiol. Rev. 72:1992;231-300.
8. Finckenberg P., Lassila M., Inkinen K., Pere A.-K., Krogerus L., Lindgren L., Mervaala E., Vapaatalo H., Nurminen M.-L., Ahonen J. Cyclosporine A induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high sodium diet. Transplantation. 71:2001;951-958.
9. FitzGerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345:2001;433-442.
10. Gavras H., Brunner H.R. Novartis award lecture: role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure. Hypertension. 37:2001;342-345.
11. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:1999;698-701.
12. Griendling K.K., Sorescu D., Lassègue B., Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 20:2000;2175-2183.
13. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase. Role in cardiovascular biology and disease. Laragh J.H., Brenner B.M. Circ. Res. 86:2000;494-501.
14. Hall J., Guyton A. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. Laragh J.H. Hypertension: Pathophysiology, Diagnosis, and Management. 1990;1105-1129 Raven Press, New York.
15. Harris R.C. Cyclooxygenase-2 in the kidney. J. Am. Soc. Nephrol. 11:2000;2387-2394.
16. Hilgers K.F., Hartner A., Porst M., Mai M., Wittmann M., Hugo C., Ganten D., Geiger H., Veelken R., Mann J.F. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int. 58:2000;2408-2419.
17. Imig J.D. Eicosanoid regulation of the renal vasculature. Am. J. Physiol., Renal Physiol. 279:2000;F965-F981.
18. Iniguez M.A., Punzon C., Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J. Immunol. 163:1999;111-119.
19. Irani K. Oxidant signalling in vascular cell growth, death, and survival. A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signalling. Circ. Res. 87:2000;179-183.
20. Kömhoff M., Wang J.L., Cheng H.F., Langenbach R., McKanna J.A., Harris R.C., Breyer M.D. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int. 57:2000;414-422.
21. Kunsch C., Medford R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. 85:1999;753-766.
22. Lee M.A., Bohm M., Paul M., Bader M., Ganten U., Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am. J. Physiol. 270:1996;E919-E929.
23. Luft F.C., Mervaala E., Müller D., Gross V., Schmidt F., Park J.-K., Schmitz C., Lippoldt A., Breu V., Deschend R., Dragun D., Schneider W., Ganten D., Haller H. Hypertension-induced end-organ damage: a new transgenic approach to an old problem (review). Hypertension. 33:1999;212-218.
24. Makino N., Sugano M., Otsuka S., Hata T. Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension. 30:1997;796-802.
25. Mervaala E.M.A., Müller D.N., Park J.-K., Schmidt F., Löhn M., Breu V., Dragun D., Ganten D., Haller H., Luft F.C. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 33:1999;389-395.
26. 1 receptor blockade modify pressure-natriuresis by different mechanisms in rats with human renin and angiotensinogen genes. J. Am. Soc. Nephrol. 10:1999;1669-1680.
27. Mervaala E.M.A., Müller D.N., Schmidt F., Park J.-K., Gross V., Bader M., Breu V., Ganten D., Haller H., Luft F.C. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension. 35:2000;587-594.
28. Mitchell J.A., Larkin S., Williams T.J. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem. Pharmacol. 50:1995;1535-1542.
29. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286:2001;954-959.
30. Mullins J.J., Peters J., Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse ren-2 gene. Nature. 344:1990;541-544.
31. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
32. Pere A.-K., Lindgren L., Tuomainen P., Krogerus L., Rauhala P., Laakso J., Karppanen H., Vapaatalo H., Ahonen J., Mervaala E.M.A. Dietary potassium and magnesium supplementations in cyclosporine-induced hypertension and nephrotoxicity. Kidney Int. 58:2000;2462-2472.
33. Pinto Y.M., Buikema H., van Gilst W.H., Scholtens E., van Geel P.P., de Graeff P.A., Wagner J., Paul M. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J. Mol. Med. 75:1997;371-377.
34. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., Harrison D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J. Clin. Invest. 97:1996;1916-1923.
35. Romero J.C., Reckelhoff J.F. Role of angiotensin and oxidative stress in essential hypertension. Hypertension. 34:1999;943-949.
36. Schonbeck U., Sukhova G.K., Graber P., Coulter S., Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155:1999;1281-1291.
37. Schoolwerth A.C., Sica D.A., Ballermann B.J., Wilcox C.S. Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 104:2001;1985-1991.
38. 1 receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats. J. Cardiovasc. Pharmacol. 33:1999;341-351.
39. Wong S.C.Y., Fukuchi M., Melnyk P., Rodger I., Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kB in myocardium of patients with congestive heart failure. Circulation. 98:1998;100-103.
40. Wu K.K. Inducible cyclooxygenase and nitric oxide synthase. Adv. Pharmacol. 33:1995;179-207.
41. Wu K.K. Cyclooxygenase-2 induction in congestive heart failure. Friend or foe? Circulation. 98:1998;95-96.
42. Qi Z., Hao C.M., Langenbach R.I., Breyer R.M., Redha R., Morrow J.D., Breyer M.D. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J. Clin. Invest. 110:2002;61-69.